Longaeva Partners’s Pfizer PFE Stock Holding History

Longaeva Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-560,615	Closed	-$14.7M	–	387
2026 Q1	$15.7M	Buy	+560,615	New	+$14.9M	0.58%	50

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Longaeva Partners's PFE Position: Q2 2026 in Review

Longaeva Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 560,615 shares — an estimated $14.7M sold.

Longaeva Partners first reported a position in PFE in Q1 2026 and held it in 1 quarter. The position peaked at $15.7M in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Longaeva Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Longaeva Partners sold 560,615 Pfizer shares in Q2 2026, an estimated $14.7M.
Longaeva Partners first reported a position in Pfizer in Q1 2026 and held it in 1 quarter.
Longaeva Partners's Pfizer position peaked at $15.7M in Q1 2026.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.